CancerCareE is an independent cancer information resource. We don't make medical decisions — we make medical information easier to understand.

Independent cancer information. We don't make medical decisions.

Please don't send medical records through our contact channels. We don't receive or review them.

Don't send medical records — we don't receive them.

Medical Disclaimer: This tool helps identify medicine names. It does not determine whether a drug is appropriate for a particular patient, verify the contents of an individual package, or recommend starting, stopping, or changing treatment. A name match is not proof of product authenticity, regulatory approval, availability, or treatment eligibility. Always confirm with the prescribing hospital, pharmacist, or your oncologist. CancerCareE is not a hospital or medical provider and does not charge patient fees.
Editorial & Review Information
Published2026-10-24
Last Reviewed2026-10-24
Reviewed ByCancerCareE Editorial Team
Content TypeReference Tool / Patient Education
Evidence LevelWHO INN + NCI Drug Dictionary + NMPA
Lookup Tool · 25 Drugs · Prototype

Chinese Cancer Drug Name Finder: Match Chinese Drug Names to International Generic Names

Confused by a Chinese prescription or treatment plan? This reference helps you identify a Chinese cancer drug by brand name, active ingredient, or generic name — with confirmation sources and confidence levels for each match.

This tool identifies names. It does not assess treatment suitability, verify package contents, or recommend any treatment change.

Quick Answer

Search by Chinese characters, pinyin, English generic name, or brand name. The result shows the proposed match, the name type, the confidence level, the source, and — critically — what the name alone does not tell you. If no reliable match is found, the tool says so rather than guessing.

Memory Anchor

"A name identifies a substance. A product identifies a medicine. A prescription identifies a treatment plan. Only your care team can connect all three."

Who This Tool Is Not For

This tool is not for patients seeking a treatment recommendation, a clinical eligibility assessment, or a guarantee that a specific Chinese product is genuine, approved, or available. It is for patients, families, and healthcare professionals who want to understand what a medicine name in a Chinese document likely refers to — and what still needs verification.

Prototype Dataset — Pending Verification: The 25 drugs below illustrate the structure, categories, confidence levels, and search behavior of the Finder. Each entry must be verified against WHO INN, NCI Drug Dictionary, and NMPA records before publication. The confidence labels shown are illustrative and not final. Do not use this dataset to make any clinical, purchasing, or regulatory decision.

Search the Drug Reference

Use any drug name available in your document. Chinese characters are usually the most useful starting point when the original document is in Chinese.

Search & Filter
Showing 25 of 25 drugs (prototype dataset, pending verification).
Immunotherapy Confirmed name match
帕博利珠单抗
Pinyin: pàbólìzhū dānkàng
Pembrolizumab
Multilingual equivalents
FAپمبرولیزوماب ARبيمبروليزوماب TRPembrolizumab RUПембролизумаб
Name type and category

Chinese generic name; immune checkpoint inhibitor; anti-PD-1 monoclonal antibody.

Identification note

The Chinese generic name should be distinguished from any specific commercial product or formulation (e.g., Keytruda). A name match confirms the active substance, not the product.

What must be checked separately

The exact product, manufacturer, formulation, regulatory status, and the treatment indication described in the relevant official documentation.

Question to ask your oncologist or pharmacist

"Does the document specify the manufacturer, formulation, and approval status of this product, and does it match the pembrolizumab formulation we would use?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Immunotherapy Confirmed name match
纳武利尤单抗
Pinyin: nàwǔlìyóu dānkàng
Nivolumab
Multilingual equivalents
FAنیوولوماب ARنيفولوماب TRNivolumab RUНиволумаб
Name type and category

Chinese generic name; anti-PD-1 immune checkpoint inhibitor.

Identification note

Distinguish the generic name from the brand name Opdivo. Confirm whether the document references a specific product or a generic equivalent.

What must be checked separately

Product identity, formulation, regulatory status in China, and the approved indication in the relevant documentation.

Question to ask your oncologist or pharmacist

"Is the product in my document Opdivo or another manufacturer, and does the formulation match?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Immunotherapy Confirmed name match
信迪利单抗
Pinyin: xìndílì dānkàng
Sintilimab
Multilingual equivalents
FAسینتیلیماب ARسينتيليماب TRSintilimab RUСинтилимаб
Name type and category

Chinese generic name; anti-PD-1 immune checkpoint inhibitor; developed in China (Innovent).

Identification note

The generic name should be separated from brand (Tyvyt) and manufacturer details.

What must be checked separately

Product identity, regulatory documentation in China and abroad, and the indication specified in the treatment plan.

Question to ask your oncologist or pharmacist

"Is this the Tyvyt product, and what indications has it been approved for in the relevant jurisdiction?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Immunotherapy Confirmed name match
替雷利珠单抗
Pinyin: tìléilìzhū dānkàng
Tislelizumab
Multilingual equivalents
FAتیزلیزوماب ARتيسليزوماب TRTislelizumab RUТислелизумаб
Name type and category

Chinese generic name; anti-PD-1 immune checkpoint inhibitor (BeiGene).

Identification note

Distinguish from brand (Tevimbra) and from manufacturer-specific formulations.

What must be checked separately

Product identity, approval status in China and other jurisdictions, and the documented indication.

Question to ask your oncologist or pharmacist

"Is this Tevimbra, and which indications is it approved for in the country of treatment?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Immunotherapy Confirmed name match
卡瑞利珠单抗
Pinyin: kǎruìlìzhū dānkàng
Camrelizumab
Multilingual equivalents
FAکامرلیزوماب ARكامريليزوماب TRKamrelizumab RUКамрелизумаб
Name type and category

Chinese generic name; anti-PD-1 immune checkpoint inhibitor (Jiangsu Hengrui).

Identification note

Distinguish from brand (AiRuiKa / SHR-1210 research code) and from other PD-1 inhibitors.

What must be checked separately

Whether the document refers to an approved product or a trial compound; approval status and indication.

Question to ask your oncologist or pharmacist

"Is this an approved product in the country of treatment, or an investigational compound in a trial?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Immunotherapy Probable match
特瑞普利单抗
Pinyin: tèruìpǔlì dānkàng
Toripalimab
Multilingual equivalents
FAتوریپالیماب ARتوريباليماب TRToripalimab RUТорипалимаб
Name type and category

Chinese generic name; anti-PD-1 immune checkpoint inhibitor (Junshi Biosciences).

Identification note

The Chinese name is recognized, but the product may also appear under the brand name Tuoyi or under the research code JS001. Confirm which is used in the document.

What must be checked separately

Whether the document is referring to an approved product, a brand, or an investigational use.

Question to ask your oncologist or pharmacist

"Is the product Tuoyi or another formulation, and is it approved for the intended indication?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Confirmed name match
奥希替尼
Pinyin: àoxītìní
Osimertinib
Multilingual equivalents
FAاوسیمرتینیب ARأوسيميرتينيب TROsimertinib RUОсимертиниб
Name type and category

Chinese generic name; EGFR tyrosine kinase inhibitor (third generation).

Identification note

Distinguish from brand (Tagrisso) and from earlier-generation EGFR TKIs (gefitinib, erlotinib). The name identifies the active substance, not the patient's molecular test result or eligibility for treatment.

What must be checked separately

Product identity and formulation, relevant product documentation, and the clinical context in which the medicine is proposed (including EGFR mutation status).

Question to ask your oncologist or pharmacist

"Does my EGFR test result support osimertinib, and does the document confirm the Tagrisso formulation?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Confirmed name match
阿来替尼
Pinyin: ālái tìní
Alectinib
Multilingual equivalents
FAالکتیب ARأليكتينيب TRAlektinib RUАлектиниб
Name type and category

Chinese generic name; ALK tyrosine kinase inhibitor.

Identification note

Distinguish from other ALK inhibitors (crizotinib, ceritinib, lorlatinib). Confirm the specific ALK inhibitor in the document.

What must be checked separately

Product identity, approval status, and whether the document's dosing matches the alectinib regimen.

Question to ask your oncologist or pharmacist

"Is this alectinib (Alecensa) or another ALK inhibitor, and does my ALK test result support it?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Confirmed name match
吉非替尼
Pinyin: jífēi tìní
Gefitinib
Multilingual equivalents
FAگفیتینیب ARجيفيتينيب TRGefitinib RUГефитиниб
Name type and category

Chinese generic name; first-generation EGFR tyrosine kinase inhibitor.

Identification note

Distinguish from brand (Iressa) and from third-generation EGFR TKIs. Its role in treatment depends on the specific EGFR mutation.

What must be checked separately

Whether the current standard of care for the patient's mutation favors a first- or third-generation EGFR TKI.

Question to ask your oncologist or pharmacist

"Given my EGFR mutation, is first-generation gefitinib the appropriate choice, or would a third-generation option be considered?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Confirmed name match
伊马替尼
Pinyin: yīmǎtìní
Imatinib
Multilingual equivalents
FAایماتینیب ARإيماتينيب TRİmatinib RUИматиниб
Name type and category

Chinese generic name; BCR-ABL / KIT / PDGFR tyrosine kinase inhibitor.

Identification note

Distinguish from brand (Gleevec / Glivec) and from generics manufactured in China. Many Chinese generics exist; confirm the manufacturer.

What must be checked separately

Which manufacturer produced the product, its regulatory status in China, and whether the intended indication matches the approved one.

Question to ask your oncologist or pharmacist

"Which manufacturer produced this imatinib, and has it been approved for my indication?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Probable match
安罗替尼
Pinyin: ānluó tìní
Anlotinib
Multilingual equivalents
FAآنلوتینیب ARأنلوتينيب TRAnlotinib RUАнлотиниб
Name type and category

Chinese generic name; multi-target tyrosine kinase inhibitor (developed in China; Chia Tai Tianqing).

Identification note

Approved in China under the brand Focus V. Its international availability is limited, so the Chinese name may not have an established international brand equivalent.

What must be checked separately

Whether the document refers to the Chinese-approved product, an investigational use, or a trial. Confirm the approval status in your jurisdiction.

Question to ask your oncologist or pharmacist

"Is anlotinib approved in my country, and is it available outside China under another brand?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Probable match
吡咯替尼
Pinyin: bǐluò tìní
Pyrotinib
Multilingual equivalents
FAپیروتینیب ARبيروتينيب TRPirotinib RUПиротиниб
Name type and category

Chinese generic name; HER2 tyrosine kinase inhibitor (developed in China; Hengrui).

Identification note

Approved in China for HER2-positive breast cancer. Its role outside China is limited; confirm whether your jurisdiction recognizes the product.

What must be checked separately

Approval status outside China, and whether an alternative HER2-targeted therapy is available and appropriate in your jurisdiction.

Question to ask your oncologist or pharmacist

"Is pyrotinib available and approved in my country, and if not, what HER2-targeted alternatives exist?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Targeted therapy Ambiguous match
瑞戈非尼
Pinyin: ruìgēfēi ní
Regorafenib
Multilingual equivalents
FAرگورافنیب ARريغورافينيب TRRegorafenib RUРегорафениб
Name type and category

Chinese generic name; multi-target tyrosine kinase inhibitor.

Identification note

The name is well recognized, but its appearance in a document may also refer to a clinical trial, an off-label use, or a named-patient program. The name alone does not distinguish between these contexts.

What must be checked separately

The specific context (approved, off-label, or trial) and whether the product is the Stivarga brand or a generic equivalent.

Question to ask your oncologist or pharmacist

"In what context is regorafenib being proposed in my document — approved use, off-label, or trial?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Chemotherapy Confirmed name match
紫杉醇
Pinyin: zǐshānchún
Paclitaxel
Multilingual equivalents
FAپاکلیتاکسل ARباكليتاكسيل TRPaklitaksel RUПаклитаксел
Name type and category

Chinese generic name; taxane chemotherapy.

Identification note

Paclitaxel appears in multiple formulations — conventional, albumin-bound (nab-paclitaxel), and liposomal. The Chinese generic name alone does not distinguish the formulation.

What must be checked separately

The formulation (conventional vs. nab-paclitaxel vs. liposomal) and the dosing schedule, both of which affect administration and side-effect profile.

Question to ask your oncologist or pharmacist

"Which paclitaxel formulation is intended, and what is the administration schedule?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Chemotherapy Confirmed name match
顺铂
Pinyin: shùnbó
Cisplatin
Multilingual equivalents
FAسیس‌پلاتین ARسيسبلاتين TRSisplatin RUЦисплатин
Name type and category

Chinese generic name; platinum-based chemotherapy.

Identification note

Distinguish from carboplatin (卡铂) and oxaliplatin (奥沙利铂). The three platinum agents have different toxicity profiles and indications.

What must be checked separately

Which platinum agent is intended, and whether the renal, neurologic, and hydration considerations match your clinical status.

Question to ask your oncologist or pharmacist

"Is cisplatin the intended platinum agent, and have my kidney function and hearing been assessed for it?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Chemotherapy Confirmed name match
多西他赛
Pinyin: duōxītāsài
Docetaxel
Multilingual equivalents
FAدوستاکسل ARدوسيتاكسيل TRDosetaksel RUДоцетаксел
Name type and category

Chinese generic name; taxane chemotherapy.

Identification note

Distinguish from paclitaxel (紫杉醇). Both are taxanes but have different dosing and toxicity profiles.

What must be checked separately

The intended taxane (docetaxel vs. paclitaxel) and whether the hypersensitivity prophylaxis protocol is documented.

Question to ask your oncologist or pharmacist

"Is docetaxel the intended taxane, and what premedication protocol is planned to reduce hypersensitivity?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Antibody–drug conjugate Confirmed name match
恩美曲妥珠单抗
Pinyin: ēnměiqūtuǒzhū dānkàng
Trastuzumab emtansine (T-DM1)
Multilingual equivalents
FAتراستوزوماب امتانسین ARتراستوزوماب إمتانسين TRTrastuzumab emtansin RUТрастузумаб эмтанзин
Name type and category

Chinese generic name; HER2-targeted antibody–drug conjugate (ADC).

Identification note

Distinguish from trastuzumab (曲妥珠单抗, without the cytotoxic payload) and from other HER2 ADCs (e.g., trastuzumab deruxtecan / DS-8201).

What must be checked separately

Which HER2-targeted agent is intended, and whether the treatment setting (adjuvant vs. metastatic) matches the approved indication.

Question to ask your oncologist or pharmacist

"Is this T-DM1 (Kadcyla) or another HER2 ADC, and does it match the treatment setting?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Antibody–drug conjugate Confirmed name match
维迪西妥单抗
Pinyin: wéidíxītuǒ dānkàng
Disitamab vedotin (RC48)
Multilingual equivalents
FAدیسیتاماب ودوتین ARديسيتاماب فيدوتين TRDisitamab vedotin RUДиситамаб ведотин
Name type and category

Chinese generic name; HER2-targeted ADC (developed in China; RemeGen).

Identification note

Also known by the research code RC48. Approved in China for HER2-expressing cancers. Its international availability is limited.

What must be checked separately

Whether the document refers to the Chinese-approved product (Aidixi) or an investigational use; and the approval status in your jurisdiction.

Question to ask your oncologist or pharmacist

"Is disitamab vedotin approved in my country, and is it available outside China?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Antibody–drug conjugate Probable match
戈沙妥珠单抗
Pinyin: gēshātuǒzhū dānkàng
Sacituzumab govitecan
Multilingual equivalents
FAساکیتوزوماب گوویتیکان ARساكيتوزوماب غوفيتيكان TRSasituzumab govitekan RUСацитузумаб говитекан
Name type and category

Chinese generic name; TROP2-targeted ADC.

Identification note

The Chinese name is relatively new; some documents may use the brand name Trodelvy or the research code IMMU-132.

What must be checked separately

Whether the document refers to an approved product, a trial, or an investigational use. Confirm the manufacturer and the approval status in China.

Question to ask your oncologist or pharmacist

"Is this Trodelvy or another sacituzumab govitecan product, and is it approved in my jurisdiction?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Hormonal therapy Confirmed name match
他莫昔芬
Pinyin: tāmòxīfēn
Tamoxifen
Multilingual equivalents
FAتاموکسیفن ARتاموكسيفين TRTamoksifen RUТамоксифен
Name type and category

Chinese generic name; selective estrogen receptor modulator (SERM).

Identification note

Distinguish from aromatase inhibitors (anastrozole, letrozole, exemestane) and from fulvestrant. These act by different mechanisms.

What must be checked separately

Whether the intended endocrine therapy is tamoxifen or an aromatase inhibitor, which depends on menopausal status and other clinical factors.

Question to ask your oncologist or pharmacist

"Given my menopausal status and ER/PR result, is tamoxifen the intended endocrine therapy?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Hormonal therapy Confirmed name match
来曲唑
Pinyin: láiqūzuò
Letrozole
Multilingual equivalents
FAلتروزول ARليتروزول TRLetrozol RUЛетрозол
Name type and category

Chinese generic name; third-generation aromatase inhibitor.

Identification note

Distinguish from anastrozole (阿那曲唑) and exemestane (依西美坦). All three are aromatase inhibitors but have different administration and side-effect profiles.

What must be checked separately

Which aromatase inhibitor is intended, and whether the patient's menopausal status supports its use.

Question to ask your oncologist or pharmacist

"Is letrozole the intended aromatase inhibitor, and does my menopausal status support its use?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Supportive care Confirmed name match
地塞米松
Pinyin: dìsāimǐsōng
Dexamethasone
Multilingual equivalents
FAدکسامتازون ARديكساميثازون TRDeksametazon RUДексаметазон
Name type and category

Chinese generic name; corticosteroid used in supportive care (anti-emetic, anti-inflammatory, premedication).

Identification note

Dexamethasone appears in many oncology regimens as supportive care, not as an anticancer therapy. Its role depends on the regimen context.

What must be checked separately

The dose, route, duration, and purpose of dexamethasone in the regimen (premedication, anti-emetic, or anti-inflammatory).

Question to ask your oncologist or pharmacist

"What is the purpose of dexamethasone in this regimen, and what dose and duration are intended?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Supportive care Confirmed name match
昂丹司琼
Pinyin: ángdānsīqióng
Ondansetron
Multilingual equivalents
FAاوندانسترون ARأوندانسيترون TROndansetron RUОндансетрон
Name type and category

Chinese generic name; 5-HT3 receptor antagonist used as anti-emetic.

Identification note

Ondansetron is supportive care, not an anticancer therapy. It is often prescribed alongside chemotherapy to reduce nausea and vomiting.

What must be checked separately

The dose, route, and schedule, especially if the patient has cardiac risk factors (QT prolongation).

Question to ask your oncologist or pharmacist

"Is ondansetron appropriate given my cardiac history, and what schedule is intended?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Investigational / research code Ambiguous match
SHR-1210
Research code (not a Chinese generic name)
SHR-1210 (camrelizumab research code)
Multilingual equivalents
FAکد پژوهشی SHR-1210 ARرمز البحث SHR-1210 TRAraştırma kodu SHR-1210 RUИсследовательский код SHR-1210
Name type and category

Research code, not a registered generic name. Associated with camrelizumab (卡瑞利珠单抗).

Identification note

A research code may refer to an investigational compound in a trial, not necessarily to an approved medicine. The name alone does not confirm regulatory status.

What must be checked separately

Whether the document refers to an approved camrelizumab product, a trial, or an investigational use. Confirm the trial identifier and regulatory status.

Question to ask your oncologist or pharmacist

"Is SHR-1210 in my document an approved product or a trial compound, and what is the trial identifier if applicable?"

Source: WHO INN, NCI Drug Dictionary, NMPA (pending)Last reviewed: 2026-10-24
Investigational / research code Unverified / no reliable match
XYZ-9999
Illustrative example only
XYZ-9999 (illustrative research code)
Multilingual equivalents
FAنمونهٔ فرضی ARمثال توضيحي TRÖrnek kod RUИллюстративный код
Name type and category

Illustrative research code used to demonstrate how an unverified match appears in the Finder.

Identification note

This is not a real drug code. It illustrates the "unverified" state: the Finder cannot find a reliable match and explicitly says so.

What must be checked separately

If a research code is unverified, ask the hospital or trial team for the full product name, the trial identifier, and the regulatory status.

Question to ask your oncologist or pharmacist

"Can you provide the full product name and trial identifier associated with this code?"

Source: illustrative onlyLast reviewed: 2026-10-24

Understanding Match Confidence

A confidence label communicates the strength of the identification evidence — not the clinical suitability of the medicine.

Confirmed name match

The Chinese term is supported by a reliable reference that links it to the proposed generic or active-ingredient name. This confirms the terminology match only — not the physical product, approval, or eligibility.

Probable match

The available name and supporting information point to a likely match, but one or more identifying details remain unverified. The result states what information is missing.

Ambiguous match

Two or more products or substances could plausibly match the input. The system presents the ambiguity rather than choosing one without sufficient evidence.

Unverified / no reliable match

The available sources do not support a dependable identification. The user should check the original Chinese characters, provide additional product details, or seek confirmation from the prescribing hospital or pharmacist.

What If the Drug Name Cannot Be Identified?

Some names are difficult to match because they are abbreviated, handwritten, mistranslated, written phonetically, or associated with a product that has limited public documentation. If a result is uncertain, do not rely on a guessed match.

Information that may help establish the identity

  1. The exact Chinese characters as printed in the original document.
  2. The full product or brand name.
  3. The manufacturer or marketing authorization holder.
  4. The product approval or registration number, where applicable.
  5. The formulation and strength shown on the product label.
  6. A clear image of the relevant label or document section, with unnecessary personal information removed.

If the name still cannot be verified, ask the hospital or dispensing pharmacist to confirm the medicine's generic name and exact product identity. Do not use an uncertain match to decide which medicine to purchase, administer, stop, or substitute.

Frequently Asked Questions

Can I identify a Chinese cancer medicine using only its Chinese name?

Sometimes. A recognized Chinese generic name may be sufficient to identify an active substance. A brand name, abbreviation, research code, or incomplete term may require additional information.

Does a matching international name prove that the Chinese product is approved?

No. Name matching and regulatory verification are separate tasks. Approval status must be checked against the relevant official regulatory record, including the applicable product and indication where that information is available.

Does the Finder tell me whether the medicine is available in my country?

Not automatically. Availability, authorization, supply, and reimbursement differ between countries and can change over time. Any country-specific information requires separate verification.

Can I use the Finder to decide whether a drug is right for my cancer?

No. The Finder helps identify terminology and products. It does not assess individual treatment eligibility or compare the clinical benefits and risks of different options.

Can I identify a clinical-trial drug by its code?

A research code may help locate public trial or development records, but a code alone may not establish a unique international generic name. Some investigational products have no approved INN or may be described differently across documents.

What if two medicines have similar names?

Do not assume they are the same medicine. The Finder flags ambiguous matches and requests further identifying information rather than presenting an unsupported conclusion.

Can the Finder verify that a medicine in a package is genuine?

No. A text-based name match cannot authenticate a physical product. Authenticity requires appropriate supply-chain, product, and regulatory verification.

Is the Finder a substitute for a pharmacist or oncologist?

No. It is an information reference intended to help users understand medicine names and prepare better questions for the healthcare professionals responsible for their care.

Identify the Name. Prepare the Question.

If you received a Chinese prescription or treatment plan and want help understanding what to verify before your next appointment, you can request a free information review. We do not charge patient fees, and we do not provide medical advice or guarantee access to any treatment.

Continue Exploring

Sources & Verification Standards

  1. World Health Organization — International Nonproprietary Names (INN) programme. who.int
  2. National Cancer Institute — NCI Drug Dictionary. cancer.gov
  3. National Medical Products Administration (NMPA) — China. nmpa.gov.cn
  4. CancerCareE Editorial Policy — Source-cited content; no claim of medical review unless documented.
  5. Manufacturer product information — when needed to resolve brand, formulation, or approval questions.

Note on data currency: This prototype includes 25 illustrative drug records. The production version requires a fully verified, source-cited database with per-drug review records. Verify all entries against WHO INN, NCI Drug Dictionary, and NMPA records before any clinical, purchasing, or regulatory decision.

Medical Disclaimer: This tool helps identify medicine names. It does not determine whether a drug is appropriate for a particular patient, verify the contents of an individual package, or recommend starting, stopping, or changing treatment. A name match is not proof of product authenticity, regulatory approval, availability, or treatment eligibility. Always confirm with the prescribing hospital, pharmacist, or your oncologist. CancerCareE is not a hospital or medical provider and does not charge patient fees.